Pharmaceuticals and biotechnology
-
Amgen, Merck & Co., and Lundbeck regarding the ecu Commission’s analysis in to the pharmaceutical sector.
-
Boehringer Ingelheim Pharma prior to the European Court of Justice concerning the scope of trademark owners’ legal rights with regards to parallel importers that repackage pharmaceutical products.
-
F. Hoffmann-La Roche prior to the European Court of Justice and also the Italian Antitrust Authority and courts concerning alleged anticompetitive plans between your Roche and Novartis groups concerning the pharmaceutical products Avastin and Lucentis.
-
GlaxoSmithKline in acquiring closure (without condition) from the FTC’s analysis into alleged abuse of patent litigation against generics as well as in achieving favorable settlements in related litigation winning dismissal of the class action lawsuit alleging a business-wide conspiracy to exclude Canadian imports winning dismissal of the California action by pharmacists alleging wide-reaching cost fixing of all major branded pharmaceutical companies, including prior to the California Top Court and SEC and DOJ investigations arising from the U.N. Oil-for-Food Enter in Iraq.
-
Gilead Sciences in winning dismissal on all counts of the purported class action lawsuit alleging unfair competition and cost-effective Care Act violations associated with the prices of Gilead’s hepatitis-C treatments.
-
Any adverse health care data services company in securing closure of the Federal trade commission analysis in to the company’s business practices, including alleged exclusivity provisions and alleged most-favored-nation provisions.
-
Merck & Co. regarding the numerous matters, including proceedings prior to the European Court of Justice within an attempted turnaround of EU law on patent exhaustion the interpretation of, and also the Belgian authorities’ compliance with, the EU directive around the transparency of costs of pharmaceutical products along with a reference in the Portuguese Top Court in regards to the question of if the ECJ has jurisdiction to interpret Article 33 from the Journeys Agreement.
-
Millennium Pharmaceutical prior to the European Court of Justice in regards to the aftereffect of the 1924 Europe-Liechtenstein customs union around the interpretation from the EU regulation on extra protection certificates.
-
Amgen, Merck & Co., and Lundbeck regarding the ecu Commission’s analysis in to the pharmaceutical sector.
-
Boehringer Ingelheim Pharma prior to the European Court of Justice concerning the scope of trademark owners’ legal rights with regards to parallel importers that repackage pharmaceutical products.
-
F. Hoffmann-La Roche prior to the European Court of Justice and also the Italian Antitrust Authority and courts concerning alleged anticompetitive plans between your Roche and Novartis groups concerning the pharmaceutical products Avastin and Lucentis.
-
GlaxoSmithKline in acquiring closure (without condition) from the FTC’s analysis into alleged abuse of patent litigation against generics as well as in achieving favorable settlements in related litigation winning dismissal of the class action lawsuit alleging a business-wide conspiracy to exclude Canadian imports winning dismissal of the California action by pharmacists alleging wide-reaching cost fixing of all major branded pharmaceutical companies, including prior to the California Top Court and SEC and DOJ investigations arising from the U.N. Oil-for-Food Enter in Iraq.
-
Gilead Sciences in winning dismissal on all counts of the purported class action lawsuit alleging unfair competition and cost-effective Care Act violations associated with the prices of Gilead’s hepatitis-C treatments.
-
Any adverse health care data services company in securing closure of the Federal trade commission analysis in to the company’s business practices, including alleged exclusivity provisions and alleged most-favored-nation provisions.
-
Merck & Co. regarding the numerous matters, including proceedings prior to the European Court of Justice within an attempted turnaround of EU law on patent exhaustion the interpretation of, and also the Belgian authorities’ compliance with, the EU directive around the transparency of costs of pharmaceutical products along with a reference in the Portuguese Top Court in regards to the question of if the ECJ has jurisdiction to interpret Article 33 from the Journeys Agreement.
-
Millennium Pharmaceutical prior to the European Court of Justice in regards to the aftereffect of the 1924 Europe-Liechtenstein customs union around the interpretation from the EU regulation on extra protection certificates.
-
IMS Health (now IQVIA) in the effective application for suspension towards the European Court of First Instance against a eu Commission decision imposing interim measures.
-
Lundbeck within an appeal prior to the European General Court from the European Commission’s fine in regards to the legality of so-known as reverse payment settlement contracts — the very first situation made the decision through the EC coping with these contracts.
-
Mallinckrodt/Questcor in Federal trade commission and five condition attorney general investigations (lately settled) into if the company’s acquisition, from Novartis, from the U.S. legal rights to Synacthen Depot eliminated potential competition to Questcor’s drug Acthar.
-
Merck & Co. and Schering Plough in proceedings prior to the French Competition Authority carrying out a complaint on abuse of dominance within the buprenorphine market.
-
A pharmaceutical company within an SEC analysis of alleged corruption in Belgium, Italia, and Germany.
-
A pharmaceutical company in securing closure of the Federal trade commission analysis of alleged market division having a U.S. competitor via a partnership.
-
Sanofi in effectively protecting its summary judgment win on attract the 3rd Circuit inside a $7 billion suit introduced with a competitor challenging Sanofi US’s loyalty reduced prices for its anticoagulant drug Lovenox.
-
Teladoc in winning a landmark preliminary injunction from the Texas Medical Board, stopping the implementation of the rule that will are gone for good telehealth in Texas the Board people abandoned their appeal after Teladoc’s answering brief and 12 supporting amicus briefs were filed.
See More
Resourse: https://clearygottlieb.com/practice-landing/
